ABSTRACTS Presented at the 2016 Annual Meeting of the British Society for Allergy and Clinical Immunology
ABSTRACTS Presented at the 2016 Annual Meeting of the British Society for Allergy and Clinical Immunology Contents ORAL PRESENTATIONS Adult Clinical page 1 Paediatric Clinical page 6 Basic Science page 11 Allied Health & Primary Care page 16 POSTER PRESENTATIONS Adult Clinical page 21 Paediatric Clinical page 50 Basic Science page 117 Allied Health page 125 Primary Care page 138 ORAL PRESENTATIONS Category: Adult Clinical O.001 Subcutaneous and sublingual grass pollen immunotherapy both reduce seasonal rhinitis symptoms and improve quality of life – a randomised, controlled trial Moises Calderon1, Guy Scadding1, Florentina Dumitru1, Aarif Eifan1, Kaitie Lawson5, Henry Bahnson5, Michelle Sever5, Audrey Plough2, Nadia Tchao3, Alkis Togias4, Stephen Durham1 1Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, London, UK, 2Immune Tolerance Network, Bethesda, Maryland, USA, 3Immune Tolerance Network, University of California, San Francisco, USA, 4The National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, 5Rho Federal Systems Division, Chapel Hill, NC, USA Objectives Randomised, double-blind, controlled trial of subcutaneous (SCIT) and sublingual (SLIT) grass pollen immunotherapy in participants with moderate-severe seasonal allergic rhinitis. Method 106 participants randomised to receive active-SCIT + placebo tablets (Alutard SQ® grass, ALK- Abello, Denmark), active-SLIT + placebo injections (GRAZAX®, ALK) or double-placebo. Treatment for two years, plus further assessment at year 3 (1 year after treatment). Primary endpoint: response to nasal challenge (data presented elsewhere). Secondary, unpowered clinical endpoints: weekly visual analogue scores (VAS), rhinitis quality of life (RQLQ) scores, rescue medication use and a global hay fever severity score. Adverse events recorded according to MedDRA and WAO grading.
[Show full text]